Market Cap 11.69B
Revenue (ttm) 2.17B
Net Income (ttm) 521.27M
EPS (ttm) N/A
PE Ratio 18.44
Forward PE 16.78
Profit Margin 24.04%
Debt to Equity Ratio 0.00
Volume 2,571,837
Avg Vol 2,772,376
Day's Range N/A - N/A
Shares Out 268.11M
Stochastic %K 82%
Beta 0.32
Analysts Strong Sell
Price Target $46.00

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 7000
Fax: 650 837 8300
Address:
1851 Harbor Bay Parkway, Alameda, United States
KY3000
KY3000 Nov. 14 at 3:13 PM
$STRO $EXEL needs to step up
0 · Reply
BiotechValues
BiotechValues Nov. 14 at 2:18 PM
$BCAB ChatGPT prediction and a slide from $EXEL's Nov earnings. Let's see
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:53 AM
$EXEL: The current market context shows a last close at $42.35, with an RSI of 67.34 indicating that the stock is nearing overbought territory. The 30-day moving average (MA30) is at $39.35, and the 50-day moving average (MA50) is at $39.40, suggesting a bullish trend as the price is above both MAs. The 60-day high of $43.72 presents a resistance level, while the low of $33.76 indicates a solid support base. Directional bias is moderately bullish due to the price being above the MAs and the recent price action approaching the 60D high. Suggested entry could be around $42.00 to capitalize on potential upward movement. Set a stop loss at $40.80 to manage risk. Target 1 can be set at $43.00, just below the 60D high, with Target 2 at $44.00 for further upside potential. Monitor RSI closely for signs of reversal as it approaches overbought levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:00 AM
$EXEL is currently trading at $42.97, with a high RSI of 80.63, indicating it is overbought. The 30-day moving average (MA30) is at $39.23, and the 50-day moving average (MA50) is at $39.16, both suggesting a strong bullish trend. However, the high RSI and proximity to the 60-day high of $43.22 indicate potential for a pullback. Directional bias is cautiously bearish due to the overbought RSI, despite the overall bullish trend indicated by the moving averages. Suggested entry point: $42.50, to capitalize on a potential pullback. Stop loss: $41.50, to limit downside risk. Target 1: $43.00, near the 60-day high. Target 2: $43.22, for a potential breakout. Monitor market conditions closely, as the high RSI may lead to increased volatility. https://privateprofiteers.com
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 12 at 5:58 PM
$EXEL insider sales here are just boat money and no more. they keep most of it and accumulate they know what they own
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:36 AM
$EXEL is currently trading at $42.97, with a high RSI of 80.63, indicating it is overbought. The 30-day moving average (MA30) is at $39.23, and the 50-day moving average (MA50) is at $39.16, both suggesting a strong bullish trend. However, the high RSI and proximity to the 60-day high of $43.22 indicate potential for a pullback. Directional bias is cautiously bearish due to the overbought RSI, despite the overall bullish trend indicated by the moving averages. Suggested entry point: $42.50, to capitalize on a potential pullback. Stop loss: $41.50, to limit downside risk. Target 1: $43.00, near the 60-day high. Target 2: $43.22, for a potential breakout. Monitor market conditions closely, as the high RSI may lead to increased volatility. https://privateprofiteers.com
0 · Reply
StockBraker
StockBraker Nov. 11 at 6:14 PM
$EXEL Getting there. 📈⬆️
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 10 at 9:05 PM
$EXEL read entire conf notes today any PT under 55 is absurd imo
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:36 PM
UBS has adjusted their stance on Exelixis ( $EXEL ), setting the rating to Neutral with a target price of 35 → 40.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 6:49 PM
TD Cowen has adjusted their stance on Exelixis ( $EXEL ), setting the rating to Buy with a target price of 44 → 51.
0 · Reply
Latest News on EXEL
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:06 PM EST - 9 days ago

Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript


Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 29, 2025, 5:47 PM EDT - 2 months ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.


Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 10:51 PM EDT - 3 months ago

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript


Product Performance, Big Money Lift Exelixis

May 23, 2025, 6:25 AM EDT - 6 months ago

Product Performance, Big Money Lift Exelixis


Exelixis: A Notable Quarter

May 14, 2025, 2:53 PM EDT - 6 months ago

Exelixis: A Notable Quarter


Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 8:31 PM EDT - 6 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript


EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Apr 29, 2025, 2:02 AM EDT - 7 months ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%


Exelixis Growth Continues with Big Money Boosts

Mar 19, 2025, 7:09 AM EDT - 8 months ago

Exelixis Growth Continues with Big Money Boosts


Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Feb 21, 2025, 1:30 PM EST - 9 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?


KY3000
KY3000 Nov. 14 at 3:13 PM
$STRO $EXEL needs to step up
0 · Reply
BiotechValues
BiotechValues Nov. 14 at 2:18 PM
$BCAB ChatGPT prediction and a slide from $EXEL's Nov earnings. Let's see
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:53 AM
$EXEL: The current market context shows a last close at $42.35, with an RSI of 67.34 indicating that the stock is nearing overbought territory. The 30-day moving average (MA30) is at $39.35, and the 50-day moving average (MA50) is at $39.40, suggesting a bullish trend as the price is above both MAs. The 60-day high of $43.72 presents a resistance level, while the low of $33.76 indicates a solid support base. Directional bias is moderately bullish due to the price being above the MAs and the recent price action approaching the 60D high. Suggested entry could be around $42.00 to capitalize on potential upward movement. Set a stop loss at $40.80 to manage risk. Target 1 can be set at $43.00, just below the 60D high, with Target 2 at $44.00 for further upside potential. Monitor RSI closely for signs of reversal as it approaches overbought levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:00 AM
$EXEL is currently trading at $42.97, with a high RSI of 80.63, indicating it is overbought. The 30-day moving average (MA30) is at $39.23, and the 50-day moving average (MA50) is at $39.16, both suggesting a strong bullish trend. However, the high RSI and proximity to the 60-day high of $43.22 indicate potential for a pullback. Directional bias is cautiously bearish due to the overbought RSI, despite the overall bullish trend indicated by the moving averages. Suggested entry point: $42.50, to capitalize on a potential pullback. Stop loss: $41.50, to limit downside risk. Target 1: $43.00, near the 60-day high. Target 2: $43.22, for a potential breakout. Monitor market conditions closely, as the high RSI may lead to increased volatility. https://privateprofiteers.com
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 12 at 5:58 PM
$EXEL insider sales here are just boat money and no more. they keep most of it and accumulate they know what they own
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:36 AM
$EXEL is currently trading at $42.97, with a high RSI of 80.63, indicating it is overbought. The 30-day moving average (MA30) is at $39.23, and the 50-day moving average (MA50) is at $39.16, both suggesting a strong bullish trend. However, the high RSI and proximity to the 60-day high of $43.22 indicate potential for a pullback. Directional bias is cautiously bearish due to the overbought RSI, despite the overall bullish trend indicated by the moving averages. Suggested entry point: $42.50, to capitalize on a potential pullback. Stop loss: $41.50, to limit downside risk. Target 1: $43.00, near the 60-day high. Target 2: $43.22, for a potential breakout. Monitor market conditions closely, as the high RSI may lead to increased volatility. https://privateprofiteers.com
0 · Reply
StockBraker
StockBraker Nov. 11 at 6:14 PM
$EXEL Getting there. 📈⬆️
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 10 at 9:05 PM
$EXEL read entire conf notes today any PT under 55 is absurd imo
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:36 PM
UBS has adjusted their stance on Exelixis ( $EXEL ), setting the rating to Neutral with a target price of 35 → 40.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 6:49 PM
TD Cowen has adjusted their stance on Exelixis ( $EXEL ), setting the rating to Buy with a target price of 44 → 51.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 6:06 PM
Morgan Stanley updates rating for Exelixis ( $EXEL ) to Overweight, target set at 44 → 45.
0 · Reply
Doozio
Doozio Nov. 5 at 5:47 PM
After those fat bloated 🐳 🐑 who sit and pee been SPOT da 🧠 can $EXEL 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 5:22 PM
Barclays has adjusted their stance on Exelixis ( $EXEL ), setting the rating to Equal-Weight with a target price of 40 → 41.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 4:34 PM
HC Wainwright & Co. has updated their rating for Exelixis ( $EXEL ) to Buy with a price target of 49.
0 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 4:07 PM
$EXEL Q3: Earnings & Revenue Beat, But Is It Enough? 🤔 Exelixis reported adjusted EPS of 78 cents, surpassing the Zacks Consensus Estimate of 68 cents. Net revenues hit $598M, also beating expectations, driven by a 13.5% year-over-year increase in Cabometyx sales 🚀. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2785853/exel-tops-q3-earnings-estimates-cabometyx-fuels-product-sales?cid=sm-stocktwits-2-2785853-body-19538&ADID=SYND_STOCKTWITS_TWEET_2_2785853_BODY_19538
0 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 3:07 PM
$EXEL beats again — Cabometyx driving the engine 🚀 Earnings and revenue both topped estimates in Q3, powered by strong Cabometyx sales, and management tightened 2025 guidance. Full breakdown of the numbers here 👉 https://www.zacks.com/stock/news/2785853/exel-tops-q3-earnings-estimates-cabometyx-fuels-product-sales?cid=sm-stocktwits-2-2785853-teaser-19537&ADID=SYND_STOCKTWITS_TWEET_2_2785853_TEASER_19537
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 5 at 2:48 PM
$EXEL AdamAlpha Financial upgrades the shares to all in
0 · Reply
Estimize
Estimize Nov. 5 at 12:12 AM
$EXEL reported 0.78 EPS and 597.76 revenue for Q3. http://www.estimize.com/intro/exel?chart=historical&metric_name=eps&utm_content=EXEL&utm
0 · Reply
svb64
svb64 Nov. 4 at 9:25 PM
$EXEL may be the best earnings report theyve ever had...
1 · Reply
StockBraker
StockBraker Nov. 4 at 9:23 PM
1 · Reply
Estimize
Estimize Nov. 4 at 4:00 PM
$EXEL reports after the close, Estimize Consensus +0.03 EPS and +1.71M Revs compared to WS http://www.estimize.com/exel/fq3-2025?utm_conten
0 · Reply
StockBraker
StockBraker Nov. 4 at 3:35 PM
$EXEL https://www.marketbeat.com/instant-alerts/filing-hussman-strategic-advisors-inc-purchases-42000-shares-of-exelixis-inc-exel-2025-11-04/
0 · Reply